Dianthus Therapeutics Announces Positive Phase 2 Claseprubart Data in Myasthenia Gravis

Reuters

2025/10/30

Dianthus <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Positive Phase 2 Claseprubart Data in Myasthenia Gravis

Dianthus Therapeutics Inc. has announced new data from its Phase 2 MaGic trial evaluating claseprubart in patients with generalized Myasthenia Gravis (gMG). The results, including new open-label extension data, were presented during the Myasthenia Gravis Foundation of America (MGFA) Scientific Session at the 2025 American Association of Neuromuscular and Electromagnetic Medicine (AANEM) Annual Meeting. The company highlighted the potential of 300mg/2mL Q4W dosing of claseprubart and plans to initiate a Phase 3 trial in 2026. The upcoming Phase 3 study will include two claseprubart treatment arms (300mg/2mL Q2W and 300mg/2mL Q4W) versus placebo, with a QMG ≥10 screening criterion. Dianthus also presented preclinical in vitro data suggesting efficacy benefits of upstream (active C1s) inhibition with claseprubart compared to downstream (C5) inhibition. Further details and a replay of the virtual industry forum are available on the company's website.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dianthus Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9564746-en) on October 29, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2579180997"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2579180997\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2579180997?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-30 03:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2579180997","market":"fut","top_or_hot":-1,"title":"Dianthus Therapeutics Announces Positive Phase 2 Claseprubart Data in Myasthenia Gravis","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Dianthus <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Positive Phase 2 Claseprubart Data in Myasthenia Gravis\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/DNTH\">Dianthus Therapeutics Inc.</a> has announced new data from its Phase 2 MaGic trial evaluating claseprubart in patients with generalized Myasthenia Gravis (gMG). The results, including new open-label extension data, were presented during the Myasthenia Gravis Foundation of America (MGFA) Scientific Session at the 2025 American Association of Neuromuscular and Electromagnetic Medicine (AANEM) Annual Meeting. The company highlighted the potential of 300mg/2mL Q4W dosing of claseprubart and plans to initiate a Phase 3 trial in 2026. The upcoming Phase 3 study will include two claseprubart treatment arms (300mg/2mL Q2W and 300mg/2mL Q4W) versus placebo, with a QMG ≥10 screening criterion. Dianthus also presented preclinical in vitro data suggesting efficacy benefits of upstream (active C1s) inhibition with claseprubart compared to downstream (C5) inhibition. Further details and a replay of the virtual industry forum are available on the company's website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dianthus Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9564746-en) on October 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dianthus Therapeutics Announces Positive Phase 2 Claseprubart Data in Myasthenia Gravis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDianthus Therapeutics Announces Positive Phase 2 Claseprubart Data in Myasthenia Gravis\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-10-30 03:30</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Dianthus <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Positive Phase 2 Claseprubart Data in Myasthenia Gravis\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/DNTH\">Dianthus Therapeutics Inc.</a> has announced new data from its Phase 2 MaGic trial evaluating claseprubart in patients with generalized Myasthenia Gravis (gMG). The results, including new open-label extension data, were presented during the Myasthenia Gravis Foundation of America (MGFA) Scientific Session at the 2025 American Association of Neuromuscular and Electromagnetic Medicine (AANEM) Annual Meeting. The company highlighted the potential of 300mg/2mL Q4W dosing of claseprubart and plans to initiate a Phase 3 trial in 2026. The upcoming Phase 3 study will include two claseprubart treatment arms (300mg/2mL Q2W and 300mg/2mL Q4W) versus placebo, with a QMG ≥10 screening criterion. Dianthus also presented preclinical in vitro data suggesting efficacy benefits of upstream (active C1s) inhibition with claseprubart compared to downstream (C5) inhibition. Further details and a replay of the virtual industry forum are available on the company's website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dianthus Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9564746-en) on October 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251029:nNDL8c64qp:1","article_id":"2579180997","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2579180997","pubTimestamp":1761766226,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Dianthus Therapeutics Inc. has announced new data from its Phase 2 MaGic trial evaluating claseprubart in patients with generalized Myasthenia Gravis . The results, including new open-label extension data, were presented during the Myasthenia Gravis Foundation of America  Scientific Session at the 2025 American Association of Neuromuscular and Electromagnetic Medicine  Annual Meeting. The company highlighted the potential of 300mg/2mL Q4W dosing of claseprubart and plans to initiate a Phase 3 trial in 2026. The upcoming Phase 3 study will include two claseprubart treatment arms  versus placebo, with a QMG ≥10 screening criterion. Dianthus also presented preclinical in vitro data suggesting efficacy benefits of upstream  inhibition with claseprubart compared to downstream  inhibition. Further details and a replay of the virtual industry forum are available on the company's website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. W","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4112":"金融交易所和数据","DNTH":"Dianthus Therapeutics Inc.","BK4585":"ETF&股票定投概念","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4139":"生物科技","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","NDAQ":"纳斯达克OMX交易所","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC"},"translate_title":"Dianthus Therapeutics宣布重症肌无力2期Claseprubart数据积极","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DNTH":0.9,"NDAQ":0.9},"content_text":"Dianthus Therapeutics Announces Positive Phase 2 Claseprubart Data in Myasthenia Gravis\n    \n\nDianthus Therapeutics Inc. has announced new data from its Phase 2 MaGic trial evaluating claseprubart in patients with generalized Myasthenia Gravis (gMG). The results, including new open-label extension data, were presented during the Myasthenia Gravis Foundation of America (MGFA) Scientific Session at the 2025 American Association of Neuromuscular and Electromagnetic Medicine (AANEM) Annual Meeting. The company highlighted the potential of 300mg/2mL Q4W dosing of claseprubart and plans to initiate a Phase 3 trial in 2026. The upcoming Phase 3 study will include two claseprubart treatment arms (300mg/2mL Q2W and 300mg/2mL Q4W) versus placebo, with a QMG ≥10 screening criterion. Dianthus also presented preclinical in vitro data suggesting efficacy benefits of upstream (active C1s) inhibition with claseprubart compared to downstream (C5) inhibition. Further details and a replay of the virtual industry forum are available on the company's website.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dianthus Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9564746-en) on October 29, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}